NAPSR News: Valeant will acquire Salix Pharmaceuticals

WASHINGTON - Feb. 23, 2015 - PRLog -- Valeant Pharmaceuticals will enter into a definitive agreement to acquire Salix Pharmaceuticals for $158.00 per share in cash totaling approximately $14.5 billion in enterprise value.

Salix Pharmaceuticals is a key leader in the U.S Gastrointestinal market and this acquisition represents Valeant’s initiative to strengthen their specialty market segment.  Salix’s current portfolio consists of 22 products including prescription brands Xifaxan, Uceris, Relistor, and Apris. "Salix's market-leading gastrointestinal franchise is an ideal strategic fit for Valeant's diversified portfolio of specialty products," said J. Michael Pearson, Valeant's chairman and chief executive officer. "The growing GI market has attractive fundamentals, and Salix has a portfolio of terrific products that are outpacing the market in terms of volume growth and a promising near-term pipeline of innovative products. With strong brand recognition among specialist GI prescribers, a highly rated specialty sales force, and a significant product and commercial presence across the undertreated and underserved gastrointestinal market, this acquisition offers a compelling opportunity for Valeant to create a strong platform for growth and business development."

The merger is expected to close in the second quarter of 2015 and both companies expect a smooth transition upon integration as there is no planned downsizing of Salix’s specialty sales force.

ABOUT US

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/ (http://napsronline.org/)